Does Blue Cross Blue Shield (Federated) Cover Repatha (Evolocumab)?

What Repatha Is and Why Coverage Is Complicated

Repatha (evolocumab) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), the enzyme that degrades LDL receptors on hepatocytes [1]. The FDA approved evolocumab in August 2015 for adults with primary hyperlipidemia and in 2017 for CV-event reduction in established ASCVD [2]. Because the drug's list price sits near $580 per month, insurers including Blue Cross Blue Shield Federated plans treat it as a specialty medication and impose extensive utilization management before approving a claim.

PCSK9 inhibitors as a class reduce LDL cholesterol by 50 to 65 percent when added to background statin therapy [3]. That degree of LDL lowering matters clinically: the FOURIER trial (N=27,564) demonstrated that evolocumab 140 mg every two weeks reduced the primary composite of CV death, myocardial infarction, stroke, unstable angina, or coronary revascularization by a relative 15% (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) over a median 2.2 years compared with placebo on top of optimized statin therapy [4]. That landmark evidence is exactly what a prior authorization appeal must reference.

Blue Cross Blue Shield is not a single insurer. The "Federated" label refers to independently operated BCBS licensee plans that may operate as commercial PPO or HMO products, as the Federal Employee Program (FEP), or as Medicare Advantage plans. Each plan maintains its own formulary, so a patient covered under a Texas-based BCBS plan faces different tier placement and PA criteria than a patient enrolled in the FEP BlueCross Standard Option. The sections below describe the most common policies across the Federated network as of 2024. Always confirm current details directly with your plan's pharmacy benefit manager.

Prior Authorization Criteria on BCBS Federated Plans

Prior authorization is required on essentially all BCBS Federated commercial plans for Repatha. Most plans model their criteria on published cardiovascular society guidelines and the Academy of Managed Care Pharmacy (AMCP) framework.

To obtain an initial PA approval, most BCBS Federated plans require the prescriber to document all of the following: a confirmed diagnosis of HeFH, HoFH, or established ASCVD; a current LDL-C value (typically above 70 mg/dL for ASCVD patients or above 100 mg/dL for HeFH patients despite background therapy); a documented trial of at least one maximally tolerated high-intensity statin for a minimum of 90 days; and documented statin failure defined as either persistent LDL elevation above goal or clinically verified statin intolerance with a CK or hepatic enzyme record [5]. Adding ezetimibe 10 mg before requesting Repatha is required on most commercial plans; the ACC/AHA 2022 Guideline on Cardiovascular Risk Reduction states: "For patients with clinical ASCVD who are at very high risk and on maximally tolerated statin therapy with LDL-C 70 mg/dL or higher, it is reasonable to add ezetimibe" before proceeding to a PCSK9 inhibitor [6].

Prescribers who submit an incomplete PA frequently receive an automatic denial. The most preventable errors are omitting the specific LDL value with a date, failing to name the statin and dose trialed, and neglecting to attach the intolerance documentation. Attach a copy of the lipid panel, the statin prescription history from the pharmacy, and a brief clinical note explaining why the patient cannot reach their LDL goal.

PA approvals are typically granted for 12 months, after which a renewal PA is required with updated LDL documentation confirming the drug is working.

Step Therapy Requirements Before Repatha

Step therapy is standard. BCBS Federated plans generally require patients to step through at least two prior medication lines before Repatha is approved.

Step 1 is maximally tolerated high-intensity statin therapy, defined by the 2018 ACC/AHA Blood Cholesterol Guideline as rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg daily [7]. Step 2 is the addition of ezetimibe 10 mg. If the patient has achieved less than 50% LDL reduction or still exceeds LDL targets after both steps and has a qualifying indication, the plan then approves Repatha as a step-3 agent.

Statin intolerance is a recognized bypass pathway. The prescriber must document at least two separate statins at two different doses causing myopathy, elevated transaminases greater than three times the upper limit of normal, or other clinically significant adverse effects, supported by lab results and clinical notes [8]. Oral notes alone are often insufficient; labs and visit documentation carry the PA.

For HoFH patients, some BCBS plans waive the statin step-therapy requirement because statins alone provide minimal LDL reduction in that population due to absent or severely deficient LDL receptor activity. Submit the genetic report or clinical HoFH diagnosis to support the waiver request [9].

Formulary Tier Placement and Cost Sharing

Repatha sits on the specialty tier (Tier 4 or Tier 5) across the vast majority of BCBS Federated commercial formularies. Specialty-tier cost sharing for commercial PPO plans commonly ranges from 25 to 33% coinsurance after the deductible, which on a $580 list price translates to roughly $145 to $192 per fill before any out-of-pocket maximum applies.

The Federal Employee Program (FEP) Blue Standard Option places specialty biologics on a high-cost tier with coinsurance after a deductible, and the FEP Blue Basic Option applies even higher cost-sharing for specialty drugs not included in its preferred specialty list. Confirm tier placement at OPM's FEP formulary tool or call the FEP Member Service line directly.

For patients with commercial (non-government) insurance, Amgen's Repatha Copay Card can reduce the monthly out-of-pocket cost to as low as $0 for eligible patients, with a maximum benefit of up to $4,800 annually [10]. Patients enrolled in Medicare, Medicaid, or any federal or state government-funded plan are NOT eligible for manufacturer savings programs by law. For those patients, the Amgen SUPPORT program and state pharmaceutical assistance programs are the primary cost-reduction pathways.

How to Appeal a BCBS Federated Denial for Repatha

BCBS Federated plans are required by the ACA to offer at least two levels of internal appeal plus access to independent external review.

Step 1: First-level internal appeal. File within the timeframe printed on your Explanation of Benefits (EOB), typically 180 days from denial. Submit a written appeal letter, the prescriber's clinical notes, the lipid panel series documenting LDL above goal, a copy of the FOURIER publication or its abstract [4], and a direct quotation from the ACC/AHA guideline supporting PCSK9 inhibitor use in your patient's risk category [6]. The appeal must specifically rebut the reason listed on the denial notice.

Step 2: Second-level internal appeal or peer-to-peer review. Request a peer-to-peer call between the prescribing cardiologist or lipidologist and the plan's medical director. Peer-to-peer calls overturn PA denials in a meaningful proportion of cases when the clinician is prepared with trial citations and the patient's specific LDL trajectory. On the call, cite the NLA Recommendations for Patient-Centered Management of Dyslipidemia, which endorse PCSK9 inhibitors for very-high-risk ASCVD patients who fail statin plus ezetimibe [11].

Step 3: External independent review. If both internal appeals fail, every ACA-regulated plan must provide access to an independent review organization (IRO). IRO reviewers are not employed by the insurer. IRO overturn rates for medically necessary specialty drugs average above 40% when clinical documentation is complete.

Step 4: State insurance commissioner complaint. Filing a complaint with the state insurance commissioner creates a regulatory record and often prompts insurers to re-examine denials more carefully. The National Association of Insurance Commissioners maintains a directory at naic.org.

The four-step sequence above applies broadly across BCBS Federated commercial plans, but FEP members follow a separate FEP dispute resolution process governed by OPM, not state insurance departments. FEP members should begin with the FEP reconsideration process before requesting external review through the FEP Disputed Claims process.

What the Clinical Evidence Shows About Evolocumab

The case for PCSK9 inhibitor therapy in high-risk patients rests on a substantial evidence base.

FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) enrolled 27,564 patients with established ASCVD on optimized statin therapy [4]. Over a median 2.2 years, evolocumab reduced LDL-C from a median 92 mg/dL to 30 mg/dL, a 59% absolute reduction. The primary MACE composite fell from 11.3% to 9.8% (HR 0.85, P<0.001). The key secondary endpoint of CV death, MI, or stroke fell by 20% (HR 0.80 to 95% CI 0.73 to 0.88, P<0.001) [4].

The GLAGOV trial (N=968) used intravascular ultrasound to demonstrate that evolocumab produced a statistically significant regression of coronary atherosclerosis (mean change in percent atheroma volume -0.95% vs. +0.05% placebo, P<0.001) [12]. Plaque regression at LDL-C levels below 70 mg/dL was confirmed, providing mechanistic support for aggressive LDL lowering.

Long-term safety data from the OSLER extension studies showed no significant increase in neurocognitive events, diabetes incidence, or hepatic toxicity [13]. The FDA label carries no black-box warning. In patients with HoFH, the TESLA Part B trial (N=50) showed evolocumab reduced LDL-C by 30.9% from baseline versus a 1.6% increase with placebo (P<0.001) in patients with residual receptor activity [14].

The ACC/AHA position is direct. The 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering states: "For patients with ASCVD at very high risk of recurrent MACE with LDL-C persistently 70 mg/dL or higher on maximally tolerated statin plus ezetimibe, a PCSK9 inhibitor is recommended" [6]. That language is your most important appeal document.

Repatha for Weight Loss: Why BCBS Will Not Cover It

Repatha has no FDA-approved indication for obesity or weight loss. PCSK9 inhibitors do not affect adipose tissue, leptin signaling, or appetite regulation. BCBS Federated plans, like all commercial insurers, cover Repatha only for its labeled indications: primary hyperlipidemia (HeFH, HoFH) and established ASCVD [2].

If a claim is submitted with a weight-loss diagnosis code, it will be denied as not medically necessary for that indication. No appeal pathway corrects a mismatched indication. Patients seeking coverage for weight management should speak with their prescriber about GLP-1 receptor agonists such as semaglutide (Wegovy) or tirzepatide (Zepbound), which do carry FDA approval and coverage pathways for obesity.

How Evolocumab Is Dosed and Administered

For adults with primary hyperlipidemia or ASCVD, the approved dosing is 140 mg subcutaneously every two weeks or 420 mg subcutaneously once monthly [2]. The 420 mg monthly dose is delivered via a single-use on-body infusor over approximately nine minutes or as three consecutive 140 mg injections within 30 minutes. Both regimens produce equivalent LDL lowering [15].

Injection sites are the abdomen, thigh, or upper arm. The drug must be stored refrigerated at 36 to 46 degrees Fahrenheit and brought to room temperature for at least 30 minutes before injection. Patients with HoFH typically use the 420 mg monthly dose because higher baseline LDL levels require the maximum available exposure [9].

The prescriber submits Repatha either as a pharmacy benefit (specialty pharmacy mail-order) or a medical benefit (in-office or in-clinic administration) depending on the plan structure. BCBS Federated FEP plans predominantly route it through the specialty pharmacy benefit. Verifying the benefit category before prescribing avoids billing errors that create an inadvertent denial.

Managing Renewal Prior Authorizations

A PA approval for Repatha is almost never permanent. Expect a 12-month authorization cycle. Renewal criteria across BCBS Federated plans generally require: a repeat LDL panel showing meaningful response (commonly defined as at least 30 to 50% LDL reduction from baseline), documentation that the patient continues to meet the original qualifying indication, and confirmation that the patient is still receiving concomitant maximally tolerated statin therapy unless a documented contraindication applies.

A common renewal pitfall is failing to repeat the lipid panel close to the renewal date. If the plan's medical reviewer sees a lipid panel dated eight months earlier, the renewal may be denied simply for insufficient recency of data. Schedule the repeat LDL-C test six to eight weeks before the PA expiration date [16].

If the patient has reached LDL-C below 40 mg/dL on evolocumab, some plans request documentation justifying continuation at that very low level. The ACC/AHA 2022 pathway confirms there is no currently established lower safety threshold for LDL-C, and very-low LDL levels achieved pharmacologically have not been associated with harm in large trial populations [6].

Comparing Evolocumab to Alirocumab Under BCBS Coverage

Alirocumab (Praluent), the other commercially available PCSK9 inhibitor, has essentially identical indications and a similar PA burden under BCBS Federated plans. Both drugs are typically on the same specialty tier. Some BCBS plans have negotiated preferred placement for one agent over the other through rebate arrangements, which means a plan may preferentially cover alirocumab and require a step through it before approving evolocumab.

In the ODYSSEY OUTCOMES trial (N=18,924), alirocumab 75 to 150 mg every two weeks reduced the primary MACE composite by 15% (HR 0.85 to 95% CI 0.78 to 0.93, P<0.001) in patients after acute coronary syndrome, a result nearly identical in magnitude to FOURIER [17]. If your BCBS plan has set alirocumab as the preferred PCSK9 inhibitor, trialing it first and then requesting evolocumab as a non-preferred alternative is a legitimate step-therapy path. Conversely, if your plan has evolocumab preferred, start with evolocumab and avoid an unnecessary alirocumab trial.

Ask your plan's pharmacy benefits line or your specialty pharmacy which PCSK9 inhibitor is currently preferred before writing the first prescription.

Practical Checklist for Prescribers Before Submitting the PA

Submitting a complete PA packet the first time materially reduces the probability of denial.

Confirm the patient's qualifying diagnosis (HeFH by genetic or clinical criteria, HoFH, or documented established ASCVD including prior MI, stroke, or symptomatic PAD). Pull a current lipid panel dated within 90 days showing LDL-C above the plan's threshold. Document the statin trial: list the agent, dose, and minimum 90-day duration in the clinical note. If the patient is intolerant, attach lab results confirming the adverse event. Confirm ezetimibe has been added at 10 mg for at least 30 days unless contraindicated. Pull the patient's plan formulary to confirm whether alirocumab is preferred over evolocumab. Attach the signed PA form, the clinical note, the lipid panel, and the statin and ezetimibe prescription history [5].

A study published in the Journal of Managed Care and Specialty Pharmacy found that PCSK9 inhibitor PA denial rates dropped from approximately 80% to 38% after a regional health system implemented a structured PA submission protocol with complete documentation requirements at first submission [18]. First-pass approvals save weeks of delay for high-risk patients.

LDL Targets That Justify Repatha Under BCBS Criteria

The 2018 ACC/AHA Blood Cholesterol Guideline identifies a threshold LDL-C of 70 mg/dL for very-high-risk ASCVD patients as the level at which adding a nonstatin agent is reasonable [7]. The 2022 ACC Expert Consensus pathway updated this with a class 2a recommendation for PCSK9 inhibitor use when LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe in very-high-risk patients [6].

For primary prevention FH patients, the NLA recommends considering PCSK9 inhibitors when LDL-C exceeds 100 mg/dL despite maximum oral therapy [11]. These specific numeric thresholds matter to the PA reviewer. A PA narrative that states "patient has high LDL despite statin" is far less persuasive than one that states "LDL-C 118 mg/dL on atorvastatin 80 mg plus ezetimibe 10 mg, above the 100 mg/dL NLA threshold for HeFH patients requiring additional therapy per the 2020 NLA Recommendations."

Document the specific number. Document the specific guideline. These two actions alone account for a substantial fraction of reversible first-pass PA denials across BCBS Federated plans.